Owned by the Association for International Promotion & Study in Tumors (APSIT)
ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells
Treatment of blast phase chronic myeloid leukemia (BP-CML) remains a challenge, and the median survival is less than 6 months. Because effective treatments are lacking, we studied tight targeting of blast cris...